IN2012DN03180A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03180A IN2012DN03180A IN3180DEN2012A IN2012DN03180A IN 2012DN03180 A IN2012DN03180 A IN 2012DN03180A IN 3180DEN2012 A IN3180DEN2012 A IN 3180DEN2012A IN 2012DN03180 A IN2012DN03180 A IN 2012DN03180A
- Authority
- IN
- India
- Prior art keywords
- phenyl
- compound
- compositions
- piperazin
- pyrimidin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 abstract 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 abstract 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 abstract 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 abstract 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 abstract 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000007800 oxidant agent Substances 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09174619 | 2009-10-30 | ||
| PCT/EP2010/066435 WO2011051425A1 (fr) | 2009-10-30 | 2010-10-29 | N-oxyde de 3-(2,6-dichloro-3,5-diméthoxy-phényl)-1-{6-[4-(4-éthyl-pipérazin-1-yl)-phénylamino]-pyrimidin-4-yl}-1-méthyl-urée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03180A true IN2012DN03180A (fr) | 2015-09-25 |
Family
ID=41396002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3180DEN2012 IN2012DN03180A (fr) | 2009-10-30 | 2010-10-29 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20120220600A1 (fr) |
| EP (1) | EP2493864B1 (fr) |
| KR (1) | KR20120101367A (fr) |
| CN (1) | CN102596916B (fr) |
| ES (1) | ES2524548T3 (fr) |
| IN (1) | IN2012DN03180A (fr) |
| WO (1) | WO2011051425A1 (fr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| RU2643326C2 (ru) * | 2012-03-30 | 2018-01-31 | Новартис Аг | Ингибитор рецептора фрф для применения в лечении гипофосфатемических заболеваний |
| PE20190736A1 (es) | 2012-06-13 | 2019-05-23 | Incyte Holdings Corp | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) |
| WO2014026125A1 (fr) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Dérivés de pyrazine en tant qu'inhibiteurs de fgfr |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| KR102269032B1 (ko) | 2013-04-19 | 2021-06-24 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| MX367723B (es) | 2013-10-25 | 2019-09-03 | Novartis Ag | Compuestos de anillos fusionados bicíclicos derivados de piridilo como inhibidores de fgfr4. |
| ES2914072T3 (es) | 2014-08-18 | 2022-06-07 | Eisai R&D Man Co Ltd | Sal de derivado de piridina monocíclico y su cristal |
| EP3200786B1 (fr) | 2014-10-03 | 2019-08-28 | Novartis AG | Utilisation de dérivés pyridyle bicycliques à anneaux fusionnés en tant qu'inhibiteurs de fgfr4 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2895769T3 (es) | 2015-02-20 | 2022-02-22 | Incyte Corp | Heterociclos bicíclicos como inhibidores de FGFR |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| EP3275442B1 (fr) | 2015-03-25 | 2021-07-28 | National Cancer Center | Agent thérapeutique contre le cancer du canal cholédoque |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| RU2017134379A (ru) * | 2015-03-25 | 2019-04-03 | Новартис Аг | Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 |
| RU2730503C2 (ru) | 2015-12-17 | 2020-08-24 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Терапевтическое средство для лечения рака молочной железы |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP3777860A4 (fr) | 2018-03-28 | 2021-12-15 | Eisai R&D Management Co., Ltd. | Agent thérapeutique pour le carcinome hépatocellulaire |
| SI3788047T1 (sl) | 2018-05-04 | 2024-11-29 | Incyte Corporation | Trdne oblike inhibitorja fgfr in postopki priprave le-teh |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| WO2020185532A1 (fr) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (fr) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021113462A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Dérivés d'un inhibiteur de fgfr |
| EP4069696A1 (fr) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
| WO2021146424A1 (fr) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| CN114539258A (zh) * | 2020-11-27 | 2022-05-27 | 首药控股(北京)股份有限公司 | 一种fgfr4蛋白激酶抑制剂的多晶型物及其制备方法 |
| WO2022221170A1 (fr) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4 |
| CN113185510B (zh) * | 2021-04-12 | 2022-05-13 | 南京海纳医药科技股份有限公司 | 一种阿伐曲泊帕杂质的制备方法 |
| WO2022261159A1 (fr) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr |
| WO2022261160A1 (fr) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2306671T3 (es) * | 1999-10-07 | 2008-11-16 | Amgen Inc. | Inhibidores de triazina quinasa. |
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| CN101336237B (zh) * | 2005-12-21 | 2015-09-30 | 诺华股份有限公司 | 作为fgf抑制剂的嘧啶基芳基脲衍生物 |
-
2010
- 2010-10-29 ES ES10771744.9T patent/ES2524548T3/es active Active
- 2010-10-29 CN CN201080048756.3A patent/CN102596916B/zh not_active Expired - Fee Related
- 2010-10-29 US US13/504,258 patent/US20120220600A1/en not_active Abandoned
- 2010-10-29 KR KR1020127010832A patent/KR20120101367A/ko not_active Ceased
- 2010-10-29 WO PCT/EP2010/066435 patent/WO2011051425A1/fr not_active Ceased
- 2010-10-29 IN IN3180DEN2012 patent/IN2012DN03180A/en unknown
- 2010-10-29 EP EP10771744.9A patent/EP2493864B1/fr not_active Not-in-force
-
2014
- 2014-09-05 US US14/477,949 patent/US20140378468A1/en not_active Abandoned
-
2015
- 2015-12-16 US US14/971,412 patent/US20160102062A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011051425A1 (fr) | 2011-05-05 |
| KR20120101367A (ko) | 2012-09-13 |
| US20160102062A1 (en) | 2016-04-14 |
| EP2493864A1 (fr) | 2012-09-05 |
| US20120220600A1 (en) | 2012-08-30 |
| US20140378468A1 (en) | 2014-12-25 |
| EP2493864B1 (fr) | 2014-10-01 |
| CN102596916B (zh) | 2015-06-17 |
| ES2524548T3 (es) | 2014-12-10 |
| CN102596916A (zh) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN03180A (fr) | ||
| MX2010010317A (es) | Compuestos heterociclicos novedosos y usos de los mismos. | |
| GB0906579D0 (en) | Pharmaceuticals, compositions and methods of making and using the same | |
| UA99833C2 (en) | Pyrimidinyl pyridazinone derivates | |
| PH12012500572A1 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
| MY150136A (en) | Picolinamide derivatives as kinase inhibitors | |
| EA201071320A1 (ru) | Активаторы глюкокиназы | |
| MX2009012708A (es) | Derivados de piridazinona. | |
| MX2009013341A (es) | Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina. | |
| MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| MX2009009304A (es) | Inhibidores de cinasa pim y metodos para su uso. | |
| MX2009004807A (es) | Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa. | |
| MX388894B (es) | Fenil acetato de l-ornitina y metodos para elaborar el mismo | |
| MX2010009654A (es) | Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos. | |
| MX2010007391A (es) | Antagonistas de trpa1. | |
| MX2010007392A (es) | Antagonistas de trpa1. | |
| MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| MX2010002191A (es) | Composiciones y metodos que emplean antagonistas nmda para lograr un efecto anestesico limitado. | |
| MX342947B (es) | Tratamiento de diabetes tipo 2. | |
| MX2011007165A (es) | Derivados de piridazinona. | |
| MX2009006812A (es) | Moduladores del receptor c3a y metodos de uso de los mismos. | |
| MX2007006284A (es) | Acidos biariloximetilarenocarboxilicos. | |
| MY185134A (en) | 6-substituted phenoxychroman carboxylic acis derivatives | |
| WO2007024921A3 (fr) | Therapies combinees visant a inhiber les interactions integrine-matrice extracellulaire | |
| MY164998A (en) | Isoquinolinone derivatives as nk3 antagonists |